Lamivudine NDC 60505-3250

NDC codes

FDA NDC Directory

Product NDC (as listed)60505-3250Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60505-3250Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60505-3250-6	60505325006	60 TABLET, FILM COATED in 1 BOTTLE (60505-3250-6)Marketed from Jan 3, 2014

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lamivudine
Generic name (nonproprietary): lamivudine
Active ingredients: Lamivudine — 100 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Apotex Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202941
Marketing start: Jan 3, 2014
Listing expires: Dec 31, 2026
Other FDA classes: Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 60505-3250_57b50cc9-4140-66b7-ec3c-e10a213dae03SPL ID 57b50cc9-4140-66b7-ec3c-e10a213dae03SPL set ID 87095352-c088-74b1-7be0-d3e293a90611RxCUI 205328UNII 2T8Q726O95
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460505325006 followed by a unit qualifier and the quantity

Package 60505-3250-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 17, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [ see Clinical Studies ( 14.1 , 14.2 ) ]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency v…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202941

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202941
Product	Strength	Form · route	Labeler	Product NDC
Lamivudine	Lamivudine 100 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	51407-866